LIFR and gastric cancer: To functionally characterize the effect of BAR502 as LIFR antagonist, we have then performed in vitro assays using a human macrophage cell line, U937 cells, and liver, HEPG2, PDAC and gastric cancer, MKN45 cell lines (59).